EP 3438091 A4 20191127 - COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS
Title (en)
COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS
Title (de)
VERBINDUNG MIT ERHÖHENDER AKTIVITÄT FÜR AKTIONEN DES GLUCAGON-LIKE PEPTID-1-REZEPTORS
Title (fr)
COMPOSÉ AYANT UNE ACTIVITÉ D'AMÉLIORATION POUR DES ACTIONS DE RÉCEPTEUR DE PEPTIDE-1 DE TYPE GLUCAGON
Publication
Application
Priority
- JP 2016067130 A 20160330
- JP 2017013158 W 20170330
Abstract (en)
[origin: EP3438091A1] The present invention aims to provide a compound useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto. The present invention relates to a glucagon-like peptide-1 receptor action enhancer containing a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.
IPC 8 full level
A61K 31/18 (2006.01); A61K 31/275 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/4045 (2006.01); A61K 31/4196 (2006.01); A61K 31/4245 (2006.01); A61K 45/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 43/00 (2006.01); C07C 311/21 (2006.01); C07C 321/14 (2006.01); C07C 335/20 (2006.01); C07D 209/20 (2006.01); C07D 213/50 (2006.01); C07D 213/74 (2006.01); C07D 249/12 (2006.01); C07D 271/06 (2006.01); C07D 295/135 (2006.01); C07D 307/52 (2006.01)
CPC (source: EP US)
A61K 31/18 (2013.01 - EP US); A61K 31/275 (2013.01 - EP US); A61K 31/341 (2013.01 - EP US); A61K 31/381 (2013.01 - EP US); A61K 31/4045 (2013.01 - EP US); A61K 31/405 (2013.01 - EP US); A61K 31/4196 (2013.01 - EP US); A61K 31/4245 (2013.01 - EP US); A61K 31/4406 (2013.01 - EP US); A61K 31/5375 (2013.01 - EP US); A61K 31/5377 (2013.01 - EP US); A61K 45/00 (2013.01 - EP US); A61K 45/06 (2013.01 - US); A61P 3/04 (2017.12 - EP US); A61P 3/10 (2017.12 - EP US); C07C 311/13 (2013.01 - US); C07C 311/21 (2013.01 - EP US); C07C 321/14 (2013.01 - EP US); C07C 335/20 (2013.01 - EP US); C07D 209/20 (2013.01 - EP US); C07D 213/50 (2013.01 - EP US); C07D 213/56 (2013.01 - EP US); C07D 213/74 (2013.01 - EP US); C07D 249/12 (2013.01 - EP US); C07D 271/06 (2013.01 - EP US); C07D 295/135 (2013.01 - EP US); C07D 307/52 (2013.01 - EP US); C07D 333/20 (2013.01 - EP US)
Citation (search report)
- [XI] WO 2011109441 A1 20110909 - MYREXIS INC [US], et al
- [X] WO 9738984 A1 19971023 - DU PONT MERCK PHARMA [US]
- [X] WO 2013170112 A1 20131114 - ABBVIE INC [US]
- [A] WO 2008109991 A1 20080918 - UNIV HEALTH NETWORK [CA], et al
- [X] WO 0017159 A1 20000330 - TULARIK INC [US]
- [X] WO 2010146236 A1 20101223 - BIOTIE THERAPIES CORP [FI], et al
- See references of WO 2017170826A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 3438091 A1 20190206; EP 3438091 A4 20191127; JP WO2017170826 A1 20190214; US 2019022039 A1 20190124; US 2020129458 A1 20200430; WO 2017170826 A1 20171005
DOCDB simple family (application)
EP 17775360 A 20170330; JP 2017013158 W 20170330; JP 2018509412 A 20170330; US 201816144314 A 20180927; US 201916728836 A 20191227